Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27041637 | 0.97 | GRM1 (0.41) | GRM1ALDH1A1USP2LMNACYP1A2 | |
| SCHEMBL19614682 | 0.83 | GRM1 (0.34) | GRM1ALDH1A1USP2LMNACYP1A2 | |
| SCHEMBL1393075 | 0.77 | USP2 (0.35) | GRM1ALDH1A1USP2LMNACYP1A2 | |
| SCHEMBL20120455 | 0.76 | GRM1 (0.39) | GRM1ALDH1A1 | |
| SCHEMBL31623879 | 0.75 | GRM1 (0.35) | GRM1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6802948 | 0.75 | USP2 (0.34) | GRM1ALDH1A1USP2LMNACYP1A2 | |
| SCHEMBL5811941 | 0.75 | ALDH1A1 (0.59) | ALDH1A1LMNATSHRSMN1; SMN2 | |
| SCHEMBL18202993 | 0.74 | GRM1 (0.38) | GRM1ALDH1A1 | |
| SCHEMBL17298359 | 0.74 | — | — | |
| SCHEMBL9142496 | 0.73 | GRM1 (0.50) | GRM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712961-A2 | KRAS G12S AND G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2024238633-A2 | KRAS G12S AND G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-25 | — | — | US | disclosed |
| EP-4313968-A2 | SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022208269-A2 | SUBSTITUTED 1-ARYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1'-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2022-10-06 | — | — | WO | disclosed |
| US-9458104-B2 | Carboxamide or sulfonamide substituted nitrogen-containing 5-membered heterocycles as modulators for the orphan nuclear receptor RORγ | PHENEX PHARMACEUTICALS AG (DE) | 2016-10-04 | — | — | US | disclosed |
| US-20150344423-A1 | CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA | PHENEX PHARMACEUTICALS AG (DE) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | HAVCR2, HDGF, HCCS | GRM1 3833/4885ALDH1A1 382/4885USP2 4023/4885 |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | GRM1 2010/4885ALDH1A1 3909/4885USP2 1504/4885 |
| US-20150344423-A1 | CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA | RORA, RORB, RORC | GRM1 228/4885ALDH1A1 1474/4885USP2 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.